CR1 and chronic myelogenous leukemia, BCR-ABL1 positive: A simpler, faster, and cheaper FACS panel detecting CD26+ and CD35+ surface markers can possibly work as an applicable clinical tool to quantify leukemic and non-leukemic stem cells in CML patients.